Loading...
Market
What percentage of patients will report significant improvement with Nyxoah's Genio device by end of 2025?
2
Resolution / Starting Odds
Less than 50% • 25%
50% to 70% • 25%
71% to 90% • 25%
More than 90% • 25%
Clinical trial results or patient surveys published by Nyxoah
Story
Nyxoah Launches App-Controlled Genio Device in UK for Sleep Apnoea Relief, Fitting First Patients
Dec 13, 2024, 09:57 AM
Nyxoah has announced the commercial launch of its innovative therapy, Genio, in the United Kingdom. This new app-controlled nerve stimulator aims to provide relief for millions suffering from sleep apnoea. The device works by stimulating the nerves in the tongue, helping patients breathe more easily during the night. The first patients in the UK have already been fitted with this microchip, marking a significant advancement in the treatment options available for sleep apnoea. This development is expected to bring relief not only to patients but also to their partners, who often endure the effects of snoring associated with the condition.
View original story
Similar markets
Less than 20% • 25%
20% to 30% • 25%
31% to 40% • 25%
More than 40% • 25%
Less than 40% • 25%
40% to 60% • 25%
61% to 80% • 25%
More than 80% • 25%
Less than 40% • 25%
40% to 50% • 25%
50% to 60% • 25%
More than 60% • 25%
Less than 60% • 25%
60% to 70% • 25%
70% to 80% • 25%
More than 80% • 25%
Less than 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
More than 75% • 25%
≥ 40% • 25%
30-39% • 25%
20-29% • 25%
< 20% • 25%
≥ 50% • 50%
< 50% • 50%
0-25% • 25%
26-50% • 25%
51-75% • 25%
76-100% • 25%
Less than 50% • 25%
50% - 60% • 25%
60% - 70% • 25%
More than 70% • 25%
0-10 patients • 25%
11-20 patients • 25%
21-30 patients • 25%
More than 30 patients • 25%
≥ 40% • 50%
< 40% • 50%